PERCHERON THERAPEUTICS LIMITED (PER)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

PER - PERCHERON THERAPEUTICS LIMITED

FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: -0
Index:

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.074

21 Nov
2024

-0.004

OPEN

$0.08

-5.13%

HIGH

$0.08

3,344,629

LOW

$0.07

TARGET
$0.19 156.8% upside
OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AFP . AGH . AGN . ARX . AVH . BIO . BOT . CSL . CUV . DXB . EOF . GSS . HXL . IDT . IMM . IMU . IVX . LGP . MAP . MDC . MSB . MVP . MYX . NEU . NUZ . NXS . OCC . OPT . OSL . PAR . PNV . PYC . RAC . RCE . SPL . TLX . TRP . VIT . ZNO .
FNARENA'S MARKET CONSENSUS FORECASTS
PER: 1
Title FY23
Actual		 FY24
Actual		 FY25
Forecast		 FY26
Forecast
EPS (cps) xxx - 1.4 - 1.2 xxx
DPS (cps) xxx 0.0 0.0 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A N/A xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title 201920202021202220232024
EPS Basic xxxxxxxxxxxxxxx-1.4
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx0.0 M
Book Value Per Share xxxxxxxxxxxxxxx1.0
Net Operating Cash Flow xxxxxxxxxxxxxxx-10.1 M
Net Profit Margin xxxxxxxxxxxxxxx-

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201920202021202220232024
Return on Capital Employed xxxxxxxxxxxxxxx-123.27 %
Return on Invested Capital xxxxxxxxxxxxxxx-122.96 %
Return on Assets xxxxxxxxxxxxxxx-87.09 %
Return on Equity xxxxxxxxxxxxxxx-123.27 %
Return on Total Capital xxxxxxxxxxxxxxx-152.45 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-10.1 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201920202021202220232024
Short-Term Debt xxxxxxxxxxxxxxx0 M
Long Term Debt xxxxxxxxxxxxxxx0 M
Total Debt xxxxxxxxxxxxxxx0 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx12 M
Price To Book Value xxxxxxxxxxxxxxx5.46

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201920202021202220232024
Capex xxxxxxxxxxxxxxx0.0 M
Capex % of Sales xxxxxxxxxxxxxxx-
Cost of Goods Sold xxxxxxxxxxxxxxx0 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx15 M
Research & Development xxxxxxxxxxxxxxx11 M
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

2
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Morgans

xx/xx/xxxx

1

xxxxxxxxxxx xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Bell Potter

08/07/2024

1

Initiation of coverage with Speculative Buy

$0.14

89.19%

Bell Potter initiates coverage on biotechnology company Percheron Therapeutics with a Speculative Buy rating and 14c target.

Progress was slowed during the pandemic, notes the broker, but data from a phase 2b trial on ATL1102 in the second half of 2024 is expected to support further investment and a future partnering transaction.

The company is seeking to develop ATL1102 for the treatment of Duchenne Muscular Dystrophy (DMD).

DMD is a degenerative neuromuscular disorder caused by a mutation in the gene responsible for production of dystrophin (a protein essential to human life), explain the analysts.

FORECAST
Bell Potter forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -0.40 cents.
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

1

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Wilsons

11/11/2024

1

Overweight

$0.25

237.84%

Wilsons highlights Percheron Therapeutics' recent capital raise of $13m, ensuring funding into 2025 as the company approaches its December Phase IIb topline data readout for avicursen in non-ambulatory Duchenne muscular dystrophy (DMD).

Positive data could demonstrate a stabilisation in upper limb function, representing a significant de-risking catalyst for avicursen and a potential breakthrough in DMD treatment, explains the analyst.

The 48-participant trial spans 16 sites across five countries, with additional 12-month data anticipated by mid-2025 to support regulatory and market expansion, suggests the broker.

Wilsons maintains an Overweight rating and lowers the target price to 25c from 27c, reflecting recent share dilution.

FORECAST
Wilsons forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -3.10 cents.
Wilsons forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -2.10 cents.
Access Extra Coverage Research History >

PER STOCK CHART

FNArena News on PER

1
Australian Broker Call *Extra* Edition – Nov 12, 2024

Nov 12 2024 - Daily Market Reports
2
Australian Broker Call *Extra* Edition – Oct 10, 2024

Oct 10 2024 - Daily Market Reports
3
FNArena Corporate Results Monitor – 02-09-2024

Sep 02 2024 - Australia
4
Australian Broker Call *Extra* Edition – Jun 11, 2024

Jun 11 2024 - Daily Market Reports
5
Australian Broker Call *Extra* Edition – Apr 08, 2024

Apr 08 2024 - Daily Market Reports

Latest Pharmaceuticals & Biotech/Lifesciences News

1
Dr Boreham’s Crucible: Arovella Therapeutics

Aug 29 2024 - Small Caps
2
ResMed’s Margin Upside Excites

Aug 07 2024 - Australia
3
Dr Boreham’s Crucible: Aroa Biosurgery

Jul 29 2024 - Small Caps
4
CSL Shares Breaking Free

Jul 23 2024 - Technicals
5
Dr Boreham’s Crucible: SDI

Jul 19 2024 - Small Caps
6
‘Defensive’ Pharmaceutical Wholesalers In Focus

Jul 18 2024 - Australia
7
Twists And Turns Of Telix And Australian Biotech

Jul 10 2024 - Small Caps
8
Dr Boreham’s Crucible: Radiopharm Theranostics

Jul 03 2024 - Small Caps
9
Dr Boreham’s Crucible: Island Therapeutics

Jun 17 2024 - Small Caps
10
Dr Boreham’s Crucible: Amplia Therapeutics

Jun 05 2024 - Small Caps